Nevus-associated Lentigo Maligna and Lentigo Maligna Melanoma, Clinicopathological Features

Authors

  • Iara R.T. Drakensjö Skin Cancer Center, Karolinska University Hospital, Stockholm, Sweden; Department of Clinical and Surgical Pathology, Unilabs, Stockholm, Sweden
  • Mari-Anne Hedblad Department of Clinical and Surgical Pathology, Unilabs, Stockholm, Sweden
  • Eugenia Colón Cervantes Department of Clinical and Surgical Pathology, Unilabs, Stockholm, Sweden
  • Ada Girnita 1Skin Cancer Center, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

DOI:

https://doi.org/10.2340/actadv.v104.18381

Keywords:

De novo melanoma, Lentigo maligna melanoma, Nevi, Nevus associated melanoma

Abstract

Nevus-associated lentigo maligna and lentigo maligna melanoma (NALMM) are rarely described in the literature and are considered an incidental finding. This study aimed to evaluate the frequency of NALMM and its clinicopathological features. A total of 201 histopathology reports were reviewed and among them 20% of the samples corresponded to NALMM, with females overrepresented in this group (p = 0.02). A significant association was also observed between NALMM with the presence of multiple nevi (p = 0.01), and dysplastic nevi (p = 0.04). Moreover, the risk of developing a second melanoma of nevus-associated type was 4.3 times higher in patients with NALMM. These results indicate that NALMM is more frequent than previously reported, suggesting that the associated nevus could interact or even act as a precursor for LM/LMM. Future studies with larger samples allied to techniques like confocal microscopy and molecular analysis are essential to determine this biological link between nevus and LM/LMM.

Downloads

Download data is not yet available.

Author Biographies

Iara R.T. Drakensjö, Skin Cancer Center, Karolinska University Hospital, Stockholm, Sweden; Department of Clinical and Surgical Pathology, Unilabs, Stockholm, Sweden

PhD student at Karolinska Institutet, onco-pathology department

Ada Girnita, 1Skin Cancer Center, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

 

 

References

Requena C, Manrique E, Nagore E. Update on lentigo maligna: diagnostic signs and treatment. Actas Dermosifiliogr 2023; 114: 413-424. DOI: https://doi.org/10.1016/j.ad.2023.04.023

https://doi.org/10.1016/j.ad.2023.02.019 DOI: https://doi.org/10.1016/j.ad.2023.02.019

Menzies SW, Liyanarachchi S, Coates E, Smith A, Cooke-Yarborough C, Lo S, et al. Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. Melanoma Res 2020; 30: 193-197.

https://doi.org/10.1097/CMR.0000000000000619 DOI: https://doi.org/10.1097/CMR.0000000000000619

Hedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. J Am Acad Dermatol 2012; 67: 60-68.

https://doi.org/10.1016/j.jaad.2011.06.029 DOI: https://doi.org/10.1016/j.jaad.2011.06.029

Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011, 24: 879-897.

https://doi.org/10.1111/j.1755-148X.2011.00880.x DOI: https://doi.org/10.1111/j.1755-148X.2011.00880.x

Purdue MP, From L, Armstrong BK, Kricker A, Gallagher RP, McLaughlin JR et al. Genes, Environment, and Melanoma Study Group. Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005; 14: 2015-2022.

https://doi.org/10.1158/1055-9965.EPI-05-0097 DOI: https://doi.org/10.1158/1055-9965.EPI-05-0097

Pampena R, Kyrgidis A, Lallas A, Moscarella E, Argenziano G, Longo C. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. J Am Acad Dermatol 2017; 77: 938-945.

https://doi.org/10.1016/j.jaad.2017.06.149 DOI: https://doi.org/10.1016/j.jaad.2017.06.149

Lallas A, Zalaudek I, Cota C, Moscarella E, Tiodorovic-Zivkovic D, Catricalà C, et al. Naevus-associated lentigo maligna: coincidence or continuum? Hippokratia 2011; 15: 373-375.

Krengel S, Hauschild A, Schafer, T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol 2006; 155: 1-8.

https://doi.org/10.1111/j.1365-2133.2006.07218.x DOI: https://doi.org/10.1111/j.1365-2133.2006.07218.x

Augustsson A, Stierner U, Rosdahl I, Suurküla M. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol 1991; 71: 518-524.

https://doi.org/10.2340/0001555571518524 DOI: https://doi.org/10.2340/0001555571518524

Krüger S, Garbe C, Büttner P, Stadler R, Guggenmoos-Holzmann I, Orfanos CE. Epidemiologic evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma: results of a case control study in melanoma patients and nonmelanoma control subjects. J Am Acad Dermatol 1992; 26: 920-926.

https://doi.org/10.1016/0190-9622(92)70133-Z DOI: https://doi.org/10.1016/0190-9622(92)70133-Z

Tsao Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003; 139: 282-288.

https://doi.org/10.1001/archderm.139.3.282 DOI: https://doi.org/10.1001/archderm.139.3.282

Gaudy-Marqueste C, Madjlessi N, Guillot B, Avril MF, Grob JJ. Risk factors in elderly people for lentigo maligna compared with other melanomas: a double case-control study. Arch Dermatol 2009; 145: 418-423.

https://doi.org/10.1001/archdermatol.2009.1 DOI: https://doi.org/10.1001/archdermatol.2009.1

Nicholls EM. Development and elimination of pigmented moles, and the anatomical distribution of primary malignant melanoma. Cancer 1973; 32: 191-195.

https://doi.org/10.1002/1097-0142(197307)32:1<191::AID-CNCR2820320129>3.0.CO;2-W

Dadzie OE, Goerig R, Bhawan J. Incidental microscopic foci of nevic aggregates in skin. Am J Dermatopathol 2008; 30: 45-50.

https://doi.org/10.1097/DAD.0b013e31815f9854 DOI: https://doi.org/10.1097/DAD.0b013e31815f9854

Yus ES, del Cerro M, Simón RS, Herrera M, Rueda M. Unna's and Miescher's nevi: two different types of intradermal nevus: hypothesis concerning their histogenesis. Am J Dermatopathol 2007; 29: 141-151.

https://doi.org/10.1097/DAD.0b013e31803325b2 DOI: https://doi.org/10.1097/DAD.0b013e31803325b2

Shreberk-Hassidim R, Ostrowski SM, Fisher DE. The complex interplay between nevi and melanoma: risk factors and precursors. Int J Mol Sci 2023; 24: 3541.

https://doi.org/10.3390/ijms24043541 DOI: https://doi.org/10.3390/ijms24043541

Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med 2015; 373: 1926-1936.

https://doi.org/10.1056/NEJMoa1502583 DOI: https://doi.org/10.1056/NEJMoa1502583

Shitara D, Tell-Martí G, Badenas C, Enokihara MM, Alós L, Larque AB, et al. Mutational status of naevus-associated melanomas. Br J Dermatol 2015; 173: 671-680.

https://doi.org/10.1111/bjd.13829 DOI: https://doi.org/10.1111/bjd.13829

Massi G, LeBoit PE. Histological diagnosis of nevi and melanoma (2nd ed. 2014). Berlin/Heidelberg: Springer, 2013.

https://doi.org/10.1007/978-3-642-37311-4 DOI: https://doi.org/10.1007/978-3-642-37311-4

Nicholls EM. Development and elimination of pigmented moles, and the anatomical distribution of primary malignant melanoma. Cancer 1973; 32: 191-195.

https://doi.org/10.1002/1097-0142(197307)32:1<191::AID-CNCR2820320129>3.0.CO;2-W DOI: https://doi.org/10.1002/1097-0142(197307)32:1<191::AID-CNCR2820320129>3.0.CO;2-W

Augustsson A, Stierner U, Rosdahl I, Suurküla M. Regional distribution of melanocytic naevi in relation to sun exposure, and site-specific counts predicting total number of naevi. Acta Derm Venereol 1992; 72: 123-127.

https://doi.org/10.2340/0001555572123127 DOI: https://doi.org/10.2340/0001555572123127

Echeverría B, Botella-Estrada R, Serra-Guillén C, Martorell A, Traves V, Requena C, et al. Increased risk of developing a second primary cutaneous nevus-associated melanoma in patients previously diagnosed with the disease. Actas Dermosifiliogr 2010; 101: 710-716. DOI: https://doi.org/10.1016/S1578-2190(10)70701-0

https://doi.org/10.1016/j.ad.2010.03.020 DOI: https://doi.org/10.1016/j.ad.2010.03.020

Cymerman RM, Shao Y, Wang K, Zhang Y, Murzaku EC, Penn LA, et al. De novo vs nevus-associated melanomas: differences in associations with prognostic indicators and survival. J Natl Cancer Inst 2016; 27: 108-110.

https://doi.org/10.1093/jnci/djw121 DOI: https://doi.org/10.1093/jnci/djw121

Friedman RJ, Rigel DS, Kopf AW, Lieblich L, Lew R, Harris MN, et al. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi. Arch Dermatol 1983; 119: 455-462. DOI: https://doi.org/10.1001/archderm.119.6.455

https://doi.org/10.1001/archderm.1983.01650300009007 DOI: https://doi.org/10.1001/archderm.1983.01650300009007

Bosch-Amate X, Podlipnik S, Riquelme-McLoughlin C, Carrera C, Barreiro-Capurro A, García-Herrera A, et al. Clinicopathological, genetic and survival advantages of naevus-associated melanomas: a cohort study. Acta Derm Venereol 2021; 31: 101-103.

https://doi.org/10.2340/00015555-3780 DOI: https://doi.org/10.2340/00015555-3780

Sagebiel RW. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness. J Invest Dermatol 1993; 100: 322-325. DOI: https://doi.org/10.1111/1523-1747.ep12470218

https://doi.org/10.1038/jid.1993.56 DOI: https://doi.org/10.1038/jid.1993.56

Lin WM, Luo S, Muzikansky A, Lobo AZ, Tanabe KK, Sober AJ, et al. Outcome of patients with de novo versus nevus-associated melanoma. J Am Acad Dermatol 2015; 72: 54-58.

https://doi.org/10.1016/j.jaad.2014.09.028 DOI: https://doi.org/10.1016/j.jaad.2014.09.028

Drakensjö IRT, Rosen E, Frohm Nilsson M, Girnita A. Ten-year follow-up study of Grenz ray treatment for lentigo maligna and early lentigo maligna melanoma. Acta Derm Venereol 2020; 100: adv00282.

https://doi.org/10.2340/00015555-3631 DOI: https://doi.org/10.2340/00015555-3631

Bax MJ, Johnson TM, Harms PW, Schwartz JL, Zhao L, Fullen DR, et al. Detection of occult invasion in melanoma in situ. JAMA Dermatol 2016; 152: 1201-1208.

https://doi.org/10.1001/jamadermatol.2016.2668 DOI: https://doi.org/10.1001/jamadermatol.2016.2668

Tohme S, Simmons RL, Tsung A. Surgery for cancer: a trigger for metastases. Cancer Res 2017; 77: 1548-1552.

https://doi.org/10.1158/0008-5472.CAN-16-1536 DOI: https://doi.org/10.1158/0008-5472.CAN-16-1536

Saida T. Histogenesis of cutaneous malignant melanoma: The vast majority do not develop from melanocytic nevus but arise de novo as melanoma in situ. J Dermatol 2019; 46: 80-94.

https://doi.org/10.1111/1346-8138.14737 DOI: https://doi.org/10.1111/1346-8138.14737

Published

2024-04-17

How to Cite

Drakensjö, I. R., Hedblad, M.-A. ., Colón Cervantes, E., & Girnita, A. (2024). Nevus-associated Lentigo Maligna and Lentigo Maligna Melanoma, Clinicopathological Features. Acta Dermato-Venereologica, 104, adv18381. https://doi.org/10.2340/actadv.v104.18381

Issue

Section

Articles

Categories